Obesity: Rubensian beauty turned into major health problem

BEAUTY AND THE BELLY

The Dutch painter Sir Peter Paul Rubens (June 28, 1577 – May 30, 1640), the most famous artist of the Flemish Baroque art school, studied anatomy and medicine to understand the human body and devoted his life to sharing views common among his contemporaries. Rubens believed that physical weakness could lead to spiritual weakness. He painted nudes and highlighted their physical beauty, goodness, temptation, desire, and fertility. His full-figured women were later called “Rubenesque” or “Rubensian” (1). His most famous “Rubensian” paintings are Venus, Cupid, Bacchus, and Ceres (painted in 1612), Amor and Venus (1614), Venus at the Mirror (1615), and The Three Graces (1635). Today Rubens is more widely known as the painter of “big” women than for his religious and mythological paintings, portraits, self-portraits, and landscapes (2).

“RUBENSIAN” BODY TYPE IS APPLE SHAPED

Both developed and developing countries are suffering from obesity or a “Rubensian” epidemic and we must face its health and economic consequences at local, national, and global levels (3). In 2017, the proportion of overweight or obese individuals has increased approximately 10% (from 66.7% to 76.8%) for men, and 9% (from 54.8% to 63.4%) for women compared with data for 1991–93 and 2011–13 in the UK (4). An excess of visceral fat is known as central obesity; the abdomen protrudes excessively as the “pot belly” or “beer belly.” This body type is also known as “apple shaped” as opposed to “pear shaped” in which fat is deposited on the hips and buttocks. Scientists have come to recognize that body fat rather than body weight is the key to evaluating obesity (5).

In healthy, non-overweight humans, white adipose tissue (WAT) accounts for as much as 20% of the body weight in men and 25% in women. The brown adipose tissue (BAT) contains multiple lipid droplets, high density vasculature, and mitochondrial cytochromes (6). WAT and BAT have antagonistic functions. WAT stores surplus energy as triglycerides, and an excessive volume of WAT is associated with increased risk of obesity-related disorders. BAT is specialized for releasing energy through the production of heat during adaptive thermogenesis and is associated with a decreased risk of obesity-related disorders. WAT is the main component of the abdominal obesity type, colloquially known as belly fat. Intra-abdominal obesity, or visceral or intra-abdominal fat, is fat tissue stored around abdominal and thoracic organs, as opposed to subcutaneous fat (located underneath the skin) or intramuscular fat (interposed in skeletal muscle) (5,7). BAT is mainly stored in mediastinal, pericardial, para-aortic, interscapular, and supraclavicular areas and around the kidneys and pancreas. BAT decreases with the increase in body weight and advanced age (8,9). Adipose tissue can expand many-fold during adulthood and is evaluated by the waist-hip ratio (WHR) and body mass index (BMI).

ADIPOSE TISSUE IS ACTING AS AN ORGAN

Accumulation of adipose tissue in individuals with obesity is associated with a state of persistent low-grade inflammation that seems to play a pivotal role in the
pathogenesis of obesity-linked insulin resistance, diabetes, and cardiovascular and neurodegenerative diseases (10). In this condition, adipose tissue is no longer considered only as a fat storage, but as an endocrine organ responsible for the synthesis and secretion of several hormones. Leptin and renin-angiotensin system control nutritional intake and insulin sensitivity. Tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), resistin, visfatin, and adiponectin are mediators of the inflammatory process responsible for persistent low-grade inflammation (11).

DEATH SENTENCE WRITTEN ON THE BELLY

Obesity may not be the Black Death (the plague disease, caused by *Yersinia pestis*), nevertheless, it is a public health crisis. The Black Death was one of the most devastating pandemics in Eurasia; in the period between 1346 and 1353, an estimated 75 to 200 million people died (12,13).

Most of the world’s population live in countries where being overweight or obese kills more people than other diseases. Since 1980, obesity has doubled worldwide; in 2014, over 600 million people were obese, ie, 13% of the world population, and more than 1.9 billion adults were overweight, of whom 39% were aged 18 years or older (14).

The number of people with diabetes mellitus is increasing as the incidence of obesity is increasing. The World Health Organization (WHO) reported that the number of people with diabetes mellitus increased 4-fold from 1980 to 2014. In 2012, 1.5 million deaths were caused directly by diabetes and 2.2 million deaths were attributable to high blood glucose. Ten years from now, the 7th leading cause of death will be diabetes. The WHO estimated 108 million people lived with diabetes in 1980 and reported 422 million diabetic people in 2014. Diabetes has become a global issue and, although the number of “Rubensians” is rapidly increasing in high-income countries, we can also observe the same trend in middle- and low-income countries (15). One of the most devastating consequences of diabetes is the lower extremity amputation (LEA). The development of atherosclerosis can lead to vessel blockade and limb amputation becomes necessary because arterial reconstruction would not lead to a better result (16,17).

The major complications of diabetes are heart attack, stroke, kidney failure, blindness, and neurodegenerative diseases. In 2012, an estimated 17.5 million people died from cardiovascular diseases (CVD), 7.4 million from coronary heart disease, and 6.7 million from stroke. Globally, more people die annually from CVD than from any other cause; CVD is responsible for 31% of global deaths. Three quarters of CVD deaths occurred in low- and middle-income countries (18).

The coming epidemic is neurodegenerative diseases. By 2025, the percentage of people in the EU population aged over 65 years is predicted to increase from 15.4% to 22.4%, which is likely to correlate with a rise in Alzheimer disease (AD), accounting for one-half to three-quarters of all dementia cases (19). Midlife obesity can lead to the development of AD, the silent killer of nerve cells. AD is also called “type 3 diabetes” because obese people with metabolic syndrome (also known as insulin resistance syndrome) are at higher risk for developing the disease (20). AD starts damaging the brain quietly more than a decade before the first symptoms appear. Lipid rafts are one of the key players in the pathogenesis of several neurodegenerative diseases, including AD. Lipid rafts represent a platform for protein-lipid and protein-protein interactions and have roles in cellular signaling. Lipid rafts are responsible for generation of the amyloid β peptide. As “Rubensian” individuals get older, their brain tissue has fewer nerve cells and synapses in comparison with a healthy brain, and abnormal clusters of protein fragments called plaques build up between nerve cells (21).

REDUCING THE “RUBENSIAN” BEAUTY BELLY AND DIABETES

One of the most commonly used oral antidiabetic medicines for the treatment of insulin resistance diabetes is metformin. Metformin stimulates AMP-activated protein kinase (AMPK) that inhibits lipid synthesis through phosphorylation and inactivation of key lipogenic enzymes (22). It could reduce visceral fat probably through a mechanism that shifts fat oxidation in WAT as surplus energy and up-regulates the adaptive thermogenesis in BAT. Therefore, metformin could be a good candidate for the treatment of a calorie surplus or age-related obesity (23).

Liraglutide, another widely used antidiabetic drug in type 2 diabetes, is an incretin mimetic and helps the pancreas to release the right amount of insulin after consumption of carbohydrates. Liraglutide is also successfully used in non-diabetic obesity for weight loss (24). Its mechanism in weight loss not completely understood but it is known that liraglutide inhibits the glucagon release, decreases food intake through the early sensation of satiety, delays gastric emptying, and reduces WAT accumulation through increasing lipolysis of adipocytes (25).
The “Rubensian beauty” is not merely an individual problem. It has become epidemic! New approaches are required to investigate the complex origin of obesity and related diseases, as obesity rates continue to rise in both the developed and the developing world.

References
1. Cohen RS. Rubens’s France: Gender and personification in the Marie de Médicis Cycle. Art Bull. 2003;85:490-522. doi:10.2307/377384
2. Camara E. The Presentation of the Portrait of Marie deMedici. Available from: https://www.khanacademy.org/humanities/ap-art-history/early-europe-and-colonial-americas/ref ormation-counter-reformation/a/rubens-the-presentation-of-the-portrait-of-marie-de-medici. Accessed: March 24, 2017.
3. Uzogara SG. Obesity epidemic, medical and quality of life consequences: a review. Int J Public Health Res. 2017;5:1-12.
4. Obesity and diabetes in 2017: a new year [editorial]. Lancet. 2017;389:1. doi:10.1016/S0140-6736(17)30004-1.
5. Carey DG. Abdominal obesity. Curr Opin Lipidol. 1998;9:35-40. Medline:9502333 doi:10.1097/00041433-199802000-00008
6. Saely CH, Geiger K, Drexel H. Brown versus white adipose tissue: a mini-review. Gerontology. 2012;58:15-23. Medline:21135534 doi:10.1159/000321319
7. Lean MEJ. Brown adipose tissue in humans. Proc Nutr Soc. 1989;48:243-56. Medline:2678120 doi:10.1016/S0308-8146(89)80036
8. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004;84:277-359. Medline:14715917 doi:10.1152/physrev.00015.2003
9. Virtanen KA, Lidell ME, Orava J, Heglid M, Westergren R, Niemi T, et al. Functional brown adipose tissue in healthy adults. N Engl J Med. 2009;360:1518-25. Medline:19357407 doi:10.1056/NEJMoa0808949
10. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92:347-55. Medline:15469638 doi:10.1079/BJN20041213
11. Coelho M, Oliveira T, Ruben Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013;9:191-200. Medline:23671428 doi:10.5114/ams.2013.3181
12. Parkhill J, Wren BW, Thomson NR, Titball RW, Holden MT, Prentice MB, et al. Genome sequence of Yersinia pestis, the causative agent of plague. Nature. 2001;413:523-7. Medline:11586360 doi:10.1038/35097083
13. Bos KI, Schuenemann VJ, Golding GB, Burbano HA, Waglechner N, Coombes BK, et al. A draft genome of Yersinia pestis from victims of the Black Death. Nature. 2011;478:506-10. Medline:21993626 doi:10.1038/nature10549
14. World Health Organization. Obesity and overweight. Fact sheet. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed: March 24, 2017.
15. World Health Organization. Diabetes. Fact sheet. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed: March 24, 2017.
16. Bild DE, Selby JV, Sinnock P, Browner WS, Braveman P, Showstack JA. Lower-extremity amputation in people with diabetes: epidemiology and prevention. Diabetes Care. 1989;12:24-31. Medline:2714164 doi:10.2337/diacare.12.1.24
17. Pandurengan K. Diabetic foot: vasculopathy assessment and analysis of risk factors of amputation. International Journal of Research in Medical Sciences. 2015;3:70-6.
18. World Health Organization. Cardiovascular diseases (CVDs) Fact sheet. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed: March 24, 2017.
19. World Health Organization. Neurological disorders public health challenge. Available from: www.who.int/mental_health/neurodiso/en/. Accessed: March 24, 2017.
20. Dailey C. The impact of Alzheimer’s disease - the silent killer. JCCC Honors Journal. 2016;7:1-14.
21. Hicks DA, Nalivvaeva NN, Turner AJ. Lipid rafts and Alzheimer’s disease: protein-lipid interactions and perturbation of signaling. Front Physiol. 2012;3:189. Medline:22737128 doi:10.3389/fphys.2012.00189
22. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125-31. Medline:11994399 doi:10.1172/Jci0215593
23. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36:843-54. Medline:21844879 doi:10.1038/ijo.2011.158
24. Iacobellis G, Mohseni M, Bianco SD, Banga PK. Liraglutide causes large and rapid epicardial fat reduction. Obesity (Silver Spring). 2017;25:311-6. Medline:28124506 doi:10.1002/oby.22178
25. Ishii H, Niya T, Ono Y, Inaba N, Jinnouchi H, Watada H. Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study. Diabetol Metab Syndr. 2017;9:3-10. Medline:28074109 doi:10.1186/s13098-016-0202-0